B型利钠肽对非心脏手术患者术后短期不良心血管事件的预测价值

目的 探讨B型利钠肽(BNP)对非急诊非心脏手术患者的心血管事件的预测价值,并分析相关的危险因素.方法 回顾性队列研究.选取2016年1月至2018年12月我院住院收治的行非急诊非心脏手术患者作为研究对象.随访12个月,按照随访中是否发生不良心血管事件(MACE)分为预后不良组(24例)和对照组(212例).分析BNP...     

B型利钠肽对老年肾损害患者心血管事件的预测价值

我们于2004-2006年对肾损害伴有心功能不全患者的B型利钠肽（BNP）进行观察,探讨其与患者再次发生心血管事件的关系。     

B型利钠肽动态变化对老年心衰患者心脏事件的预测价值

目的 评价动态多点血浆B型利钠肽(BNP)水平对老年慢性充血性心力衰竭(CHF)患者预后的预测价值.方法 顺序前瞻性选择选取94例心功能Ⅲ～Ⅳ级(NYHA分级)老年CHF住院患者,测定入院时血浆BNP水平(BNPI)、出院时BNP水平(BNP2)及出院后2 w门诊随访时测定BNP水平(BNP3),超声检测左室舒张末内径(LVEDD)和左室射血分数(LVEF),并随访.主要观察终点为心源性死亡和心衰恶化再入院.统计学分析采用双变量相关分析、多元逐步回归及COX回归分析.结果 引入变量:年龄、LVEDD、LVEF、BNP1、BNP2、BNP3,双变量相关分析与多元逐步回归分析显示,仅BNP1与心源性死亡时间及心衰再入院时间独立相关,COX回归分析同样只有BNP1(偏回归系数=0.005;P=0.000)是心脏不良事件的独立相关影响因素.结论 对老年CHF患者BNP1可作为预测心衰预后的重要、可靠指标,是心脏不良事件的独立相关影响因素.     

B型利钠肽对心力衰竭患者心源性事件的预测价值

目的:评价B型利钠肽(BNP)对左心衰竭患者的预后预测价值.方法:使用荧光免疫的方法测定心力衰竭患者的BNP,并进行随访.主要临床终点为:心源性死亡和再入院.根据随访结果将患者分为无再发事件组(162例),心源性再入院组(47例),心源性死亡组(54例).用Kaplan-Meier法计算生存率和无心脏事件生存率,多因素分析采用COX回归分析法.结果:300例患者平均随访(9.5±5.6)个月,心源性再入院组[482.0(227.0,793.0)pg/ml]及心源性死亡组[565.0(327.3,1192.5)pg/ml]的BNP水平均显著高于无再发事件组[146.5(51.7,374.3)pg/ml)(P均＜0.001).不论单因素还是多因素分析,包括年龄、性别、纽约心功能分级(NYHA)、超声心动图所测左心房前后径、左心室舒张末内径、左心室射血分数(LVEF)及Log BNP,仅Log BNP与心源性死亡时问及心源性再入院时间独立相关.当分别引入Log BNP,性别,年龄,NYHA,LVEF和左心室舒张末内径及是否伴有心房颤动、心房扑动、室性心动过速、糖尿病共10个因素,单因素分析中:Log BNP、性别、NYHA、LVEF和室性心动过速是心源性事件发生的预测因子.但进一步COX多元回归分析中,只有Log BNP(回归系数:0.9898;P=0.002)和室性心动过速(回归系数:0.893;P=0.005)是独立相关影响因素.两者中,又以Log BNP的相关性最强.根据受试者工作特征曲线(ROC),BNP 288 pg/ml为划分有无心源性事件发生的最佳阈值点.BNP≤288 pg/ml患者的无心源性事件生存时间约是＞288 pg/ml患者的两倍(18.06个月vs 9.94个月,P=0.000).结论:BNP对心力衰竭患者的预后预测价值好.Log BNP和室性心动过速是心源性死亡、再入院事件独立相关影响因素.     

老年冠心病患者非心脏手术围手术期心血管事件的预测

目的探究老年冠心病患者非心脏手术围手术期心血管事件的预测情况。方法选取非心脏手术患者100例,其中冠心病患者50例,非冠心病患者50例,对2组非心脏手术患者围手术期心血管事件的发生率等进行预测。结果实验组冠心病患者在术前1天以及术后第二天的血液NT-pro BNP水平均明显高于对照组非冠心病患者(P0.05),实验组围手术期心血管事件发生率明显高于对照组(P0.05)。结论对老年心脏病非心脏手术患者实施血液NT-pro BNP水平检测,可以较好的对患者围手术期心血管事件进行预测。     

B型利钠肽和肺毛细血管嵌压对心力衰竭远期心脏事件的预测价值

目的 研究血浆B型利钠肽(BNP)和肺毛细血管嵌压(PCWP)对慢性心力衰竭(心衰)患者远期心脏事件的预测价值.方法 入选134例心衰患者,经Swan-Ganz导管测定PCWP,双抗体夹心免疫荧光法测定血浆BNP浓度.随访3年,记录发生的心脏事件.结果 (1)心脏事件组的心胸比率、PCWP、BNP较非心脏事件组显著升高(P<0.01).(2)多元Logisac回归分析PCWP和BNP为心衰患者远期心脏事件独立的预测因子.(3)BNP、PCWP预测心原性死亡ROC曲线下面积分别为0.846和0.762.BNP取值720.5 ng/L、PCWP取值19.5 mm Hg(1 mm Hg=0.133 kPa)预测心原性死亡的敏感度和特异度达最高.(4)血浆BNP≤702.5 ng/L组心衰患者的生存率高于BNP>702.5 ng/L组,PCWP≤19.5 mm Hg组心衰患者的生存率高于PCWP>19.5 mm Hg组;Log-Rank检验说明,不同PCWP和BNP两组生存时间之间差异有统计学意义(P<0.05).结论 BNP和PCWP是影响慢性心衰患者远期心脏事件的独立预测因素.     

脑利钠肽对心力衰竭远期心脏事件的预测价值

目的:研究血浆脑利钠肽(BNP)对慢性心力衰竭(心衰)患者远期心脏事件的预测价值.方法:入选134例心衰患者,双抗体夹心免疫荧光法测定血浆BNP浓度,记录发生的心脏事件.结果:134例中随访资料完整130例,随访时间平均(708±220)d.130例中发生心脏事件者44例(心脏事件组),未发生心脏事件者86例(非心脏事件组),心脏事件组左室舒张末期内径、心胸比率、BNP均较非心脏事件组显著升高(均P<0.01).多元logistic回归分析显示,BNP为心衰患者远期心脏事件独立的预测因子.BNP预测心源性死亡ROC曲线下面积为0.846.BNP取值702.5 ng/L预测心源性死亡的敏感度和特异度达最高.血浆BNP≤702.5 ng/L患者生存率高于BNP>702.5 ng/L者(P<0.05). 结论:BNP是影响慢性心衰患者远期心脏事件的独立预测因素.     

B型利钠肽预测妊娠合并先天性心脏病相关肺动脉高压患者心血管不良事件发生的分析

目的:分析妊娠合并先天性心脏病相关肺动脉高压(CHD-PAH)患者,早中孕期B型利钠肽(BNP),在预测妊娠合并CHD-PAH妊娠期,心血管不良事件发生是否为影响因素,同时探讨该人群在妊娠期间不良事件的结局。方法:选取2015年01月至2019年12月,首都医科大学附属北京安贞医院妇产科,收治并终止妊娠的妊娠合并CHD-PAH患者,回顾性分析BNP在预测妊娠合并CHD-PAH患者,妊娠期心血管不良事件发生的影响因素。结果:共48例CHD-PAH患者发生心脏不良事件,其中8例患者死亡。当BNP≥100 ng/L不良心血管事件发生率更高,血浆BNP50ng/L的患者心血管不良事件发生率较低,BNP≥300ng/L为预测心血管不良事件独立影响因素(OR=17.348,95%CI:4.644～64.799),同时研究还发现了重度肺动脉高压为预测心血管不良事件的因素(mPAP≥80 mmHg,1 mmHg=0.133 kPa,OR=6.329,95%CI:1.822～21.988,P0.05),并且BNP≥300 ng/L的重度肺动脉高压患者发生心血管不良事件的可能性极高。结论:CHD-PAH患者应避免妊娠,如患者拒绝终止妊娠,应在妊娠期间动态评估妊娠风险,密切、充分评估心功能,作为此类患者心血管不良事件的风险因素,BNP升高预示患者心血管不良事件发生率增加,在预测妊娠期间不良心血管事件风险方面有额外的价值。     

B型利钠肽对非心源性危重患者的预后价值

目的 探讨B型利钠肽(BNP)浓度是否预测急诊非心源性危重患者的28 d病死率.方法 测量255例急诊室非心源性危重患者血中BNP浓度,并记录各项化验指标和临床生理指标.随访28 d患者是否存活,进一步分析人选时血BNP水平与28 d病死率的关系.结果 28 d共有71例死亡,死亡组患者的血BNP浓度中位数水平明显高于存活组(326.0 ng/L比50.9 ng/L,P<0.001),BNP水平预测28 d病死率的ROC曲线下面积为0.825,血BNP预测患者病死率的最佳界值点是114.0 ns/L,血BNP>114.0 ng/L(RR 7.268,95%CI 3.864～13.672)和急性生理学及慢性健康状况评分(APACHE)Ⅱ评分>20(RR 3.330,95%CI 1.815～6.109)是预测患者28 d病死率的独立危险因素.结论 血BNP水平是预测急诊非心源性危苇患者28 d病死率的独立指标,应用BNP预测危重患者病死率的能力优于急诊室常用的快速急性生理学评分与快速急诊医学评分系统,与经典的APACHE Ⅱ评分十分相近.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.     

B型利钠肽对非心源性危重患者的预后价值

Objective B-type natriuretic peptide(BNP) have been used widely in the diagnosis and prognosis of cardiogenic diseases, but the association between BNP concentrations and non-cardiogenic critical illness is unknown. Our study aims at investigating the role of natriuretic peptide testing for predicting 28-day mortality of non-cardiogenic critically ill patients in emergency department (ED). Methods A total of 255 non-cardiogenic critically ill patients treated in the emergency department were prospectively enrolled and a sample of blood was obtained for BNP measurement from each patient. A variety of clinical and laboratory variables were recorded. After 28 days, the vital status of each patient was ascertained and the association between BNP values at presentation and mortality was assessed. Results 71 patients died during the 28-day observation period. Median BNP concentrations at presentation among decedents were significantly higher than those of survivors (326. 0 ng/L versus 50. 9 ng/L,P <0. 001). The optimal BNP cut point for predicting 28-day mortality was 114. 0 ng/L. In a multivariate analysis (Cox-regression), a BNP concentration greater than 114. 0 ng/L(RR 7. 268, 95% CI 3. 864-13. 672) and an Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores greater than 20 (RR 3. 330, 95% CI 1. 815-6. 109)were the independent predictors of the 28-day mortality. BNP concentration alone had an area under the receiver operating characteristic curve (AUC) of 0. 825 for predicting mortality. Conclusions BNP concentrations at presentation are strong predictor of 28-day mortality in patients with non-cardiogenic critically ill patients in ED, which is better than Rapid Acute Physiology Score (RAPS) , Rapid Emergency Medicine Score (REMS) and APACHE Ⅱ score.